Washington: Even as President Barack Obama is plugging his signature law to lower health care costs at home, his administration is pressurising India and other countries to impose higher prices even for lifesaver cancer drugs.
Obama administration's multiple "strategies to affect drug pricing abroad by using American international political muscle", according to a Huffington Post investigative report, became apparent in a testimony by US Patent and Trademark Office deputy director Teresa Stanek Rea two weeks ago.
Thus far the Indian government has resisted American pressure and continues to offer the generic alternative.
At the hearing largely ignored by the American media, Rea said she planned to deploy the pressure it has used against India in other countries, too. "This is front and centre," Rea said.
Rea's 70-minute testimony focused on the Indian government's efforts earlier this year to create an affordable generic alternative to a Bayer AG patented expensive cancer drug called Nexavar.
Rea repeatedly castigated India's government for approving the generic drug, calling the move an "egregious" violation of World Trade Organization treaties, the Post said.
India's decision, Rea was quoted as saying, "dismayed and surprised" her, and she boasted about "personally" engaging "various agencies of the Indian government" in efforts to overturn it.
Thus far the Indian government has resisted American pressure and continues to offer the generic alternative, which was approved in March after several months of negotiations with Bayer, the Post noted.
Not once during her testimony did Rea -- or any member of the Congress -- cite the price Bayer posted in India for its version of the drug, the newspaper said.
Bayer, which earned $3.4 billion last year, was charging over $5,000 a month for standard doses, according to Indian government data cited by the Post. The cost of a generic version: $157 a month.
The Post noted that it was the high price that Bayer demanded for its cancer medication that prompted the Indian government to authorise Natco Pharma to begin selling the generic version and ordered the firm to pay Bayer a 6 percent royalty on the proceeds.
Rea's testimony is only the most explicit example of the Obama administration's efforts to use intellectual property manoeuvring to inflate medical costs abroad, the newspaper said.
Over the last year, it said, various US agencies joined in disrupting World Health Assembly talks over reducing research and development costs for medicines targeting developing nations, and shut down World Intellectual Property Organization negotiations aimed at curtailing the prices of existing drugs in poor countries.
Kangana Ranaut lodges complaint against Hrithik Roshan for circulating her photos
Aditi Rao Hydari to Vir Das: U/A for 'The Jungle Book' leaves Indian audience amused
Election script goes awry for Vijayakanth as cadre questions his 'captaincy'
Karnataka government bans surge pricing by Uber, Ola in Bengaluru
These 'Sanskari' Hollywood movie posters are just too good!
It's official: Bipasha Basu and Karan Singh Grover announce their wedding date in a joint statement
Photo of the day: Samuel L Jackson clicks selfie with 'the most beautiful' Deepika Padukone
Modi's rural income promise leaves Indian farmers, experts cold
CM Rangaswamy waits for a sign from Heaven, as surveys predict poll defeat
Anushka Sharma, Virat Kohli spotted together post break-up
Another blogger hacked and shot to death in Bangladesh
No weightage to Class XII marks in JEE ranking, students need 75% to qualify
Panama Papers: British PM Cameron admits he benefited from father's offshore account
Pak envoy says talks with India stand suspended, hints won't allow NIA visit